Genoptix, Inc. 

(Public, NASDAQ:GXDX)   Watch this stock   
Find more results for Genoptix Inc
Feb 25, 2010
Q4 2009 GENOPTIX INC Earnings Conference Call - 5:00PM EST - Add to calendar
Feb 25, 2010
Q4 2009 GENOPTIX INC Earnings Release - 11:00AM EST - Add to calendar
Jan 25, 2010
GENOPTIX INC at Jefferies Global Healthcare Services Conference
Jan 11, 2010
GENOPTIX INC at JPMorgan Healthcare Conference
Dec 8, 2009
GENOPTIX INC at Deutsche Bank Securities MedTools Investor Summit
Nov 17, 2009
GENOPTIX INC at Lazard Capital Healthcare Conference
More events from AOL Finance »    

Key stats and ratios

Q3 (Sep '09) 2008
Net profit margin 18.62% 26.99%
Operating margin 32.24% 22.92%
EBITD margin - 24.13%
Return on average assets 21.18% 25.88%
Return on average equity 23.64% 28.14%
Employees 301 -

Address

2110 Rutherford Road
Carlsbad, CA 92008
United States - Map
+1-760-2686200 (Phone)
+1-760-2686201 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com

Genoptix, Inc. discussions

  View all discussions »

Description

Genoptix, Inc. (Genoptix) is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists (hema/oncs). The Company’s hematopathologists (hempaths) utilize diagnostic technologies to provide an assessment of a patient's condition, aiding physicians in making vital decisions concerning the treatment of malignancies of the blood and bone marrow and other forms of cancer. In order for hem/oncs to make the correct diagnosis, choose or modify appropriate therapeutic regimens and monitor the effectiveness of these regimens, they require highly specialized diagnostic services. Serial blood and bone marrow examinations are performed to follow the progress of the disease and the patient’s response to therapy.

Officers and directors

Andrew E. Senyei M.D.
Chairman of the Board
Age: 59
Bio & Compensation - Reuters
Tina S. Nova Ph.D.
President, Chief Executive Officer, Director
Age: 55
Bio & Compensation - Reuters
Douglas A. Schuling
Chief Financial Officer, Senior Vice President
Age: 48
Bio & Compensation - Reuters
Samuel D. Riccitelli
Chief Operating Officer, Executive Vice President
Age: 50
Bio & Compensation - Reuters
Christian V. Kuhlen M.D., Esq.
Vice President, General Counsel, Corporate Secretary
Age: 36
Bio & Compensation - Reuters
Timothy M. Buono
Director
Age: 43
Bio & Compensation - Reuters
Robert E. Curry Ph.D.
Director
Age: 62
Bio & Compensation - Reuters
Michael A. Henos
Director
Age: 59
Bio & Compensation - Reuters
Karin Eastham CPA
Director
Age: 59
Bio & Compensation - Reuters
Laurence R. McCarthy Ph.D.
Director
Age: 64
Bio & Compensation - Reuters